MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Comparison of Current DBS Platforms in the United States

    L. Surillo, U. Yazdani, S. Chitnis (Dallas, TX, USA)

    Objective: To compare and contrast the currently available deep brain stimulation (DBS) platforms in the United States, their technical features, capabilities and practicality of usage.…
  • 2019 International Congress

    Dielectric Properties of a Blood Plasma Predict Motor Deficits in a 6-Hydroxydopamine-Induced Rat Model of Parkinson’s Disease

    E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

    Objective: This study presents a novel method of predicting the behavioral pattern in male Sprague-Dawley rats with motor deficits impairment, based on the measurement of…
  • 2019 International Congress

    Predicting the functional impact on the performance of daily activities in people with PD: a novel approach based on objective measures obtained by inertial sensors

    K. Lebel, C. Duval, E. Goubault, S. Bogard, P. Blanchet (Montreal, QC, Canada)

    Objective: To predict global motor disabilities using symptomatology assessed with inertial sensors, medication regimen, and cognitive deficits through: (1) a clustering method on performance metrics…
  • 2019 International Congress

    Substantia Nigra (SN) Hyperechogenicity as seen in Transcranial Sonography (TCS) is a reliable disease progression marker from Stage I to Stage II in Early Onset Parkinson’s Disease (EOPD)

    S. Ravi, V. Shivkumar, D. Dang, T. Gilmour, A. Espay, J. Wang, T. Subramanian, K. Venkiteswaran (Hershey, PA, USA)

    Objective: To test the hypothesis that SN hyperechogenicity seen in transcranial sonography (TCS) can be used as a reliable disease progression marker from stage I…
  • 2019 International Congress

    Speech impairment as a marker of clinical changes in premanifest Huntington’s disease

    J. Chan, Y. Lie, J. Stout, A. Vogel (Melbourne, Australia)

    Objective: Speech disturbances have been described in premanifest Huntington’s Disease (HD). Yet a recent systematic review and meta-analysis highlighted disagreement in the literature regarding the…
  • 2019 International Congress

    Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application

    NI. Inbar, N. Omer, A. Bar David, N. Geva, I. Dabakarov, L. Barsky, Z. Yekutieli, N. Giladi, T. Gurevich (Tel Aviv, Israel)

    Objective: Huntington’s disease (HD) patients cope with unique gait disturbances. Proper evaluation of gait in these patients is highly needed. Dyskinesia may negatively affect validity…
  • 2019 International Congress

    Impact of caring for patients with Huntington’s disease on work status

    K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (San Francisco, CA, USA)

    Objective: To describe changes in the employment status of family members caring for a person with Huntington’s disease (HD) in the US and Europe. Background:…
  • 2019 International Congress

    Involuntary movements with abnormal brain imaging: A Case Report

    W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

    Objective: To present a case of juvenile-onset Huntington's disease (HD) with a mixed phenotype and abnormal brain imaging. Background: HD is an autosomal-dominant neurodegenerative disorder…
  • 2019 International Congress

    Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease

    P. Carlson-Kuhta, N. Hasegawa, SH. Jung, V. Shah, A. Ragothaman, D. Peterson, K. Smulders, L. King, M. Mancini, J. Lapidus, J. Nutt, F. Horak (Portland, OR, USA)

    Objective: To investigate the effects of a 6-week cognitively challenging exercise intervention in people with Parkinson’s disease (PD). Background: Gait and balance impairments have been…
  • 2019 International Congress

    Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

    M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

    Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley